QuickView for Dihydroergotamine (compound)

DHE; NINDS_000592; Dihidroergotamina [INN-Spanish]; KBio3_001429; SPBio_001235; KBio1_000592; Diidroergotamina [DCIT]; KBio2_006673; Spectrum4_000958; BRN 5720196.
show more »

DHE; NINDS_000592; Dihidroergotamina [INN-Spanish]; KBio3_001429; SPBio_001235; KBio1_000592; Diidroergotamina [DCIT]; KBio2_006673; Spectrum4_000958; BRN 5720196; 511-12-6; C07798; 6190-39-2; Dihydroergotaminum [INN-Latin]; Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)-; KBio2_001537; DivK1c_000592; Ergotamine, 9,10-dihydro-; EINECS 208-123-3; Spectrum_001057; KBioSS_001537; Spectrum2_001188; KBio2_004105; Spectrum3_000395; Dehydroergotamine; Dihydroergotamine; KBioGR_001576; 9,10-Dihydroergotamine
show less «

Dihydroergotaminum [INN-Latin]; Dihydroergotamine mesylate; 9,10-dihydro-ergotamine; Dihydroergotamine monomethanesulfonate; Dihidroergotamina [INN-Spanish]; Dihydroergotamine methanesulfonate

Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT_1Da and 5-HT_1Db receptors. It also binds with high affinity to serotonin 5-HT_1A, 5-HT_2A, and 5-HT_{2C...
show more »}

Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT_1Da and 5-HT_1Db receptors. It also binds with high affinity to serotonin 5-HT_1A, 5-HT_2A, and 5-HT_2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT_1D receptors.
show less «

Two theories have been proposed to explain the efficacy of 5-HT_1D receptor agonists in migraine: 1) activation of 5-HT_1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT_{...
show more »}

Two theories have been proposed to explain the efficacy of 5-HT_1D receptor agonists in migraine: 1) activation of 5-HT_1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT_1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
show less «